GILEAD SCIENCES (GIS DU) stock market data APIs
€126.845
-0.3(-0.2%)
as of March 13, 2026
Try our APIs with
free plan!
GILEAD SCIENCES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.DU.
Prev. Close
126.845
Open
126.5476
High
127.3856
Low
126.4434
52 wk Range
80.3287-130.9737
Market Cap
78 028 M
Dividends (Yield)
0.0273
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES data using free add-ons & libraries
Get GILEAD SCIENCES Fundamental Data
GILEAD SCIENCES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES News
New
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Gilead Sciences, Inc.’s GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased 7% year over year to $1.8 billion (in 2025) due to ongoing competitive h...
The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F Financial
For Immediate Releases Chicago, IL – March 13, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...
How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story
In recent days, Jefferies and other Wall Street firms initiated and reiterated positive coverage on Gilead Sciences, highlighting its strong HIV franchise, deep oncology pipeline, and an intellectual-...
Top Stock Reports for Oracle, T-Mobile & Gilead
Thursday, March 12, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
